Terms: = Head and neck cancer AND NFE2L2, ENSG00000116044, 4780, Q16236, NRF2 AND Clinical Outcome
8 results:
1. clinical outcome-Related cancer Pathways and Mutational Signatures in Patients With Unresectable Esophageal Squamous Cell Carcinoma Treated With Chemoradiotherapy.
Li L; Sun J; Liu N; Yu R; Zhang J; Pang J; Ou Q; Yin Y; Cui J; Yao X; Zhao R; Shao Y; Yuan S; Yu J
Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):382-394. PubMed ID: 36167753
[TBL] [Abstract] [Full Text] [Related]
2. Signaling pathways and their potential therapeutic utility in esophageal squamous cell carcinoma.
Kadian LK; Arora M; Prasad CP; Pramanik R; Chauhan SS
Clin Transl Oncol; 2022 Jun; 24(6):1014-1032. PubMed ID: 34990001
[TBL] [Abstract] [Full Text] [Related]
3. HO-1 in lymph node metastasis predicted overall survival in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiation therapy.
Akaishi R; Fujishima F; Ishida H; Tsunokake J; Yamauchi T; Gokon Y; Ueki S; Fukutomi T; Okamoto H; Takaya K; Sato C; Taniyama Y; Nakamura T; Nakaya N; Kamei T; Sasano H
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1477. PubMed ID: 34264023
[TBL] [Abstract] [Full Text] [Related]
4. Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated nrf2-antioxidant pathway activation.
Noman ASM; Parag RR; Rashid MI; Islam S; Rahman MZ; Chowdhury AA; Sultana A; Jerin C; Siddiqua A; Rahman L; Nayeem J; Akther S; Baidya S; Shil RK; Rahman M; Shirin A; Mahmud R; Hossain SMI; Sumi SA; Chowdhury A; Basher SB; Hasan A; Bithy S; Aklima J; Chowdhury N; Hasan MN; Banu T; Chowdhury S; Hossain MM; Yeger H; Farhat WA; Islam SS
Cell Death Dis; 2020 Aug; 11(8):663. PubMed ID: 32814771
[TBL] [Abstract] [Full Text] [Related]
5. ROS-independent ER stress-mediated nrf2 activation promotes warburg effect to maintain stemness-associated properties of cancer-initiating cells.
Chang CW; Chen YS; Tsay YG; Han CL; Chen YJ; Yang CC; Hung KF; Lin CH; Huang TY; Kao SY; Lee TC; Lo JF
Cell Death Dis; 2018 Feb; 9(2):194. PubMed ID: 29416012
[TBL] [Abstract] [Full Text] [Related]
6. nrf2 promotes oesophageal cancer cell proliferation via metabolic reprogramming and detoxification of reactive oxygen species.
Kitano Y; Baba Y; Nakagawa S; Miyake K; Iwatsuki M; Ishimoto T; Yamashita YI; Yoshida N; Watanabe M; Nakao M; Baba H
J Pathol; 2018 Mar; 244(3):346-357. PubMed ID: 29243822
[TBL] [Abstract] [Full Text] [Related]
7. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
Choi M; Kadara H; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Kim K; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Herbst RS; Wistuba II
Ann Oncol; 2017 Jan; 28(1):83-89. PubMed ID: 28177435
[TBL] [Abstract] [Full Text] [Related]
8. nrf2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.
Shibata T; Kokubu A; Saito S; Narisawa-Saito M; Sasaki H; Aoyagi K; Yoshimatsu Y; Tachimori Y; Kushima R; Kiyono T; Yamamoto M
Neoplasia; 2011 Sep; 13(9):864-73. PubMed ID: 21969819
[TBL] [Abstract] [Full Text] [Related]
